Skip to main content
. Author manuscript; available in PMC: 2019 Aug 5.
Published in final edited form as: Oral Oncol. 2018 May 3;81:100–108. doi: 10.1016/j.oraloncology.2018.04.014

Table 1.

Selected protein lysine and arginine methyltransferases (PMTs): frequency of genetic/expression alterations per TCGA and clinicopathologic significance in SCCHN.

PMTs Frequency of genetic and expression alterations per TCGA Clinicopathologic significance in SCCHN
Protein lysine methyltransferases
NSD1 17% • Wild-type NSD1 mRNA levels associated with poor OS and PFS in laryngeal carcinoma [16]
• Inactivated mutant NSD1 is associated with the immune cold phenotype [18]
NSD2 6% High NSD2 protein levels associated with poor grade [19]
NSD3 17% High NSD3 protein levels associated with poor grade and heavier smoking history [20,21]
EHMT2 9% High EHMT2 protein levels associated with poor PFS and OS [22,23]
EZH2 5% High EZH2 protein levels associated with poor OS and advanced tumor size, nodal and clinical stage in oral SCCHN [26,29,31] and nasopharyngeal carcinoma [30]
Protein arginine methyltransferases
PRMT1 6% Not investigated
PRMT5 14% High nuclear PRMT5 protein levels associated with advanced clinical, lymph node stage and poor OS in nasopharyngeal [37] and oropharyngeal carcinoma [38]